Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Compugen(CGEN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CGEN
10/23/2026: CGEN (2-star) is currently NOT-A-BUY. Pass it for now.
Compugen is a clinical-stage biotechnology company that utilizes proprietary computational platforms to discover novel cancer immunotherapy targets. Its business strength lies in a unique, discovery-led pipeline, including lead candidates like COM701 and COM902, which have attracted interest from major pharmaceutical partners. The investment story centers on the potential of these novel pathways to treat solid tumors and eventually yield lucrative licensing deals or acquisitions. Primary risks include the binary nature of clinical trials, substantial cash burn, and intense competition from much larger pharmaceutical firms. The stock is best suited for risk-tolerant investors focused on biotech innovation, who should closely monitor upcoming clinical data readouts and partnership developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Compugen offers high-risk, high-reward exposure to oncology innovation but lacks the predictable revenue growth required for traditional growth investors. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts sharply to clinical trial catalysts and partnership news, making it suitable for momentum strategies during positive news cycles. |
| Value investor | Weak fit | The absence of earnings and heavy reliance on R&D spending makes traditional valuation metrics like P/E inapplicable. |
| Dividend investor | Weak fit | As a non-profitable biotech, the company does not pay dividends and reinvests all capital into clinical programs. |
| Low-risk investor | Weak fit | The inherent volatility of clinical-stage biotech stocks is unsuitable for low-risk or capital-preservation objectives. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The share price is extremely sensitive to clinical trial data readouts and biotech sector sentiment. |
| Valuation risk | Medium / high | Valuations are based on long-term clinical potential rather than current financial performance, leading to significant potential for downward adjustment. |
| Competition risk (Major Pharma) | High | Well-capitalized pharmaceutical giants dominate the oncology market and can outspend smaller firms on trial speed and scale. |
| Business quality | Medium | The company possesses a unique discovery platform, but its business model depends on successful external validation of its drugs. |
| Dividend income | Low / none | Income-focused investors should not expect cash returns. |
| Execution risk | High | Successful clinical development requires navigating complex, time-consuming, and expensive regulatory and scientific hurdles. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 112.05% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 185.66M USD | Price to earnings Ratio 5.6 | 1Y Target Price 4.6 |
Price to earnings Ratio 5.6 | 1Y Target Price 4.6 | ||
Volume (30-day avg) 206.1K shares | Beta 2.79 | 52 Weeks Range 1.43 - 3.23 | Updated Date 10/23/2026 |
52 Weeks Range 1.43 - 3.23 | Updated Date 10/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.35 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| License and Collaboration Agreements | Milestone payments and royalties from partner pharmaceutical companies for rights to drug targets or candidates. | Revenue is unpredictable and occurs in chunks based on hitting research and development milestones. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 5.6 | Forward PE 12.36 | Enterprise Value 110.33M | Price to Sales(TTM) 2.51 |
Enterprise Value 110.33M | Price to Sales(TTM) 2.51 | ||
Enterprise Value to Revenue 1.49 | Enterprise Value to EBITDA 3.6 | Shares Outstanding 94.72M | Shares Floating 94.51M |
Shares Outstanding 94.72M | Shares Floating 94.51M | ||
Percent Insiders 0.39 | Percent Institutions 15.17 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.